SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement —— Interim NEXICART-2 clinical trial results selected for oral presentation at ASH 2026 —LOS ANGELES, Nov. 12, 20…

IMMX
SquawkNews Desk

Related stories

Volkswagen Plans Up to 100,000 Job Cuts by 2030 Volkswagen plans to cut up to 100,000 jobs worldwide by 2030 as it restructures operations. The headline says four German plants are at risk. M impact | EQUITY | Nov 15, 2026, 03:31 AM UTC US Air Travel Disruptions to Persist Until Late Sunday, FAA Head Says The FAA head said disruptions to US air travel are expected to persist until late Sunday. The wire reports airlines are canceling flights. M impact | EQUITY | Nov 15, 2026, 02:42 AM UTC Air Travel Disruptions Expected to Persist Into Sunday, Officials Say Officials say thousands of flights are affected as air travel issues are expected to continue well into Sunday. M impact | EQUITY | Nov 14, 2026, 11:56 PM UTC SpaceX Starship Returns to Landing Pad After 22-Hour Orbital Voyage SpaceX’s Starship returned from a 22-hour voyage in orbit and was caught by mechanical arms at the Texas launch tower, a first for the spacecraft. M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC SpaceX Starship Returns to Landing Pad From Orbit SpaceX’s Starship returned to its landing pad from orbit, completing a test of reusable rockets. M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC Air Travel Disruptions to Persist Into Sunday, Officials Say Officials say thousands of flights have been affected, with air travel issues expected to persist well into Sunday. M impact | EQUITY | Nov 14, 2026, 09:39 PM UTC